Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

(2014) Tomas Kalincik et al.   Multiple Sclerosis Journal

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Benefit–Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis

(2012) Nawab Qizilbash et al.   CLINICAL THERAPEUTICS

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts

(2010) Jane Castelli-Haley et al.   JOURNAL OF MEDICAL ECONOMICS

Health and quality of life in patients with relapsing multiple sclerosis: making the intangible tangible

(2009) Howard Zwibel   JOURNAL OF THE NEUROLOGICAL SCIENCES

Multiple sclerosis beyond EDSS: depression and fatigue

(2009) Tjalf Ziemssen   JOURNAL OF THE NEUROLOGICAL SCIENCES

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey

(2008) Olympia Hadjimichael et al.   Health and Quality of Life Outcomes

Glatiramer Acetate

(2008) François Blanchette et al.   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY